Hepatitis E Vaccine-Hecolin® in Elderly People
On 28 Jun, 2019, an article entitled “Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years” was published by the international medical journal Vaccine (IF 3.269, JCR3) online. The study was jointly carried out by Xiamen Innovax Biotech Co.Ltd, Xiamen University, Zhejiang CDC and Kaihua CDC. Hepatitis E is an acute viral hepatitis caused by infection with a virus known as hepatitis E virus (HEV) which is transmitted via fecal-oral route. Everyone is susceptible with hepatitis E, but the older population are more susceptible and have the poor prognosis. Hecolin® has been approved for use in people aged 16 y and above in China since 2011, supported by a large Phase III clinical trial involving adults aged 16 to 65 years. The current study indicates that Hecolin® is immunogenic and well tolerated in elderly people aged greater than 65 years compared with the adults aged 16~65 years. This is good news for older folks! Please see the following link for details.
